Skip to content
Integral Biologics logo — Transforming Personal Care. The next generation of care made...

Integral Biologics

Transforming Personal Care. The next generation of care made truly personal through computational biology.

Founded 2019 United States New York, United States 2-10 employees Pre-Seed Biotechnology, Consumer Goods +2

General Information

Company Name Integral Biologics
Founded Year 2019
Location United States New York, United States
Employees 2-10
Industries Biotechnology, Consumer Goods, Health Care +1
Funding Stage Pre-Seed
Social

BounceWatch is an independent company data service, not affiliated with Integral Biologics. To contact Integral Biologics, visit an.integralpartof.me.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Integral Biologics compare?

A PDF of Integral Biologics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Integral Biologics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Integral Biologics

Integral Biologics is a biotechnology startup that aims to revolutionize the personal care industry through computational biology. Founded in 2019, the company operates at the intersection of biotechnology, consumer goods, healthcare, and wellness beauty. Its innovative approach promises to deliver a new level of personalized care. Integral Biologics secured a Pre Seed Round investment on 01 February 2019 from Mesia Ventures, reflecting investor confidence in its potential to disrupt the market.

Business keywords: Personalized Medicine, Computational Biology, Healthcare Innovation, Genomics, HealthTech, Precision Medicine

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Pre Seed Round Undisclosed 1
Mesia Ventures
01 Feb 2019

Integral Biologics Alternatives & Competitors

View All Alternatives
Integral Biologics vs
Mesh Bio
Mesh Bio Singapore

Multidimensional Health Intelligence Platform for digital twin and computational biology enabled car...

Series A
27 employees
AI, Analytics
Integral Biologics vs
Exai Bio
Exai Bio United States

Delivering next-generation liquid biopsy platform for the earliest detection and most accurate cance...

22 employees
Biotechnology, Health Care
Integral Biologics vs

We build things that matter for science and medicine.

5 employees
Biotechnology, Financial Services

FAQ About Integral Biologics

Transforming Personal Care. The next generation of care made truly personal through computational biology.
Integral Biologics was founded in 2019.
Integral Biologics is headquartered in New York, United States.
Integral Biologics operates in Biotechnology, Consumer Goods, Health Care and Wellness Beauty. Its work centres on Personalized Medicine, Computational Biology, Healthcare Innovation and Genomics.
Integral Biologics has approximately 2-10 employees.
Integral Biologics has completed 1 funding round. The latest funding stage is Pre-Seed.
Top alternatives and competitors to Integral Biologics include Mesh Bio, Exai Bio, Nancy J Kelley + Associates, Oak Bioinformatics LLC, Avenzo Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Integral Biologics and Mesh Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Integral Biologics, https://bouncewatch.com/company/integral-biologics, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout